MedTrace Logo

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-07-02

Study results available
· View outcomes & findings →

Summary

Uveitis represents a heterogeneous group of diseases that results from ocular inflammatory reaction involving ocular tissue and vasculature. The inflammation usually causes pain, redness, photophobia and blurred vision. This inflammation, is typically treated with regional or systemic therapy. The regional therapy typically consists of topical corticosteroids or periocular or regional corticosteroids. Regional therapy can lead to a steroid response glaucoma, which is increased intraocular pressure.This pilot study aims to evaluate the possible effectiveness of H.P. Acthar in patients with active ocular inflammatory disease, and currently on treatment for glaucoma or have a history of glaucoma.

Conditions

  • Uveitis
  • Anterior Uveitis
  • Intermediate Uveitis
  • Posterior Uveitis
  • Scleritis
  • Clinically Significant Macular Edema

Interventions

DRUG

H.P. ACTHAR SUBCUTANEOUS GEL INJECTION

Subcutaneous injection twice weekly

Sponsors & Collaborators

  • Mallinckrodt

    collaborator INDUSTRY

  • Tampa Bay Uveitis Center, LLC

    lead OTHER

Principal Investigators

  • Grace L Clarke · Tampa Bay Uveitis Center, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2016-12-07
Completion
2016-12-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02764697 on ClinicalTrials.gov